Skip to main content
Clinical Trials/JPRN-UMIN000044811
JPRN-UMIN000044811
Recruiting
未知

Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients - Prospective observation study for the efficacy and safety of combined therapy with Ipilimumab and Nivolumab in non-small cell lung cancer patients

Kyoto Prefectural University of Medicine0 sites50 target enrollmentJuly 9, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
on small cell lung cancer
Sponsor
Kyoto Prefectural University of Medicine
Enrollment
50
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 9, 2021
End Date
September 30, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\) Patients with active multiple cancers (hormonal therapy for prostate cancer and breast cancer is acceptable) (2\)Patients with a history of treatment with systemic chemotherapy or immune checkpoint inhibitors (However, molecularly targeted cancer drugs for patients with positive driver gene mutations and postoperative adjuvant chemotherapy for patients with postoperative recurrence are acceptable) (3\)Other patients who are judged inappropriate by the physician in charge.

Outcomes

Primary Outcomes

Not specified

Similar Trials